The annual meeting of the American Association for Cancer Research (AACR) will be held on April 5-10, 2024 local time in San Diego, USA. At the meeting, Yifang Bio will present the latest results from the Phase II clinical trial of garsorasib (D-1553) in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation. This will mark the study's (NCT05383898) appearance at a prestigious international academic conference following the World Conference on Lung Cancer (WCLC) 2022.

About Garsorasib

KRAS mutations are widespread in several highly lethal cancer types, with KRAS G12C being a specific KRAS mutation that accounts for approximately 44% of all KRAS mutations.KRAS G12C mutations are more common in lung, colorectal, pancreatic, and bile duct cancers. According to Frost & Sullivan, from 2016 to 2020, the number of incidence of major KRAS G12C-mutated cancers in China increased from 38,000 to 43,000, and is expected to reach 58,000 in 2030.The potentially huge market for KRAS G12C inhibitors has also attracted the layout of many domestic and foreign pharmaceutical companies.

D-1553 is the first KRAS G12C inhibitor independently developed and entered into clinical trials in China, and is also the first domestic KRAS G12C inhibitor to be included in the breakthrough therapeutic varieties by the Center for Drug Evaluation (CDE) of the State Administration of Pharmaceutical Affairs. 2024, D-1553 is used for patients with disease progression or intolerable disease after previous first-line systemic therapy and the presence of KRAS G12C mutation confirmed by testing. KRAS G12C mutation in locally advanced or metastatic non-small cell lung cancer was accepted and included in the priority review and approval process. In addition, international multi-center clinical studies of D-1553 alone and in combination in the first-line treatment of non-small cell lung cancer as well as other solid tumors such as colorectal cancer are underway, and some of the results have been published in highly influential international academic conference platforms one after another, which have demonstrated good safety and anti-tumor activity.

In August 2023, Chiatai Tianqing signed a license and cooperation agreement with Yifang Biologicals, obtaining the exclusive license rights for the development, registration, production and commercialization of the latter's KRAS G12C-targeting drug D-1553 in mainland China. Chiatai Tianqing will continue to develop new indications in order to further explore and maximize the clinical value of D-1553 and benefit more patients, please look forward to the publication of more research results in the future.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650365660&idx=1&sn=f5902eb2becb34af5b83bc8f05e6ab7f&chksm=885f9b6bbf28127d39e4e20fcad6addbba57ad0cc1783627d97bffffb1e297953b8ca50ce95e&mpshare=1&scene=1&srcid=0314Yl6BqYX6xl3HIqxxxczJ&sharer_shareinfo=cdf2e4563c60d0a72c0574666deed050&sharer_shareinfo_first=cdf2e4563c60d0a72c0574666deed050#rd